Clopidogrel is one of the major drugs used in the treatment of Acute Coronary Syndrome. Along with Aspirin it is the standard of care in Percutaneous Coronary Interventions with stenting, when a long term dual antiplatelet treatment is needed. However the response to clopidogrel shows wide inter-individual variations. Various studies have shown that the polymorphisms in the genes responsible for Clopidogrel absorption and metabolism are a major factor for these variations. Polymorphisms in the CYP2C19 and P2Y12 gene affect the platelet aggregometry response to Clopidogrel. This increases the risk of recurrent thrombotic events in patients who are poor responders to clopidogrel. Hence it is important to determine the relationship between these polymorphism …show more content…
The inflammation and Cholesterol containing deposits (plaque) in your arteries are usually to blame for coronary artery disease. These building up of plaques, start narrowing coronary arteries and decreasing blood flow to the heart. Eventually, this decreased blood flow may cause chest pain (angina), shortness of breath, or other diseases associated with coronary artery. A complete blockage can cause a heart attack.
ACUTE CORONARY SYNDROME (ACS):
Acute Coronary Syndrome (ACS) can be defined as a spectrum of clinical conditions from unstable angina to ST-elevation Myocardial infarction (MI) consequent to myocardial ischemia. In vivo imaging techniques applied in humans and the success of fibrinolytic and antithrombotic therapy in ACS established in practice the role of thrombosis in their pathogenesis. A number of micro anatomic mechanisms underlie acute coronary thrombosis. The rupture of plaque’s protective fibrous cap can, most commonly cause lethal coronary thrombosis, according to autopsy studies.  This physical disruption of the atherosclerotic plaque results in almost all acute coronary thrombosis. Once platelets are exposed to the ruptured